右美托咪定对脓毒症小鼠的脑保护作用

doi:10.3969/j.issn.1002-1949.2018.12.016

摘要
图/表
参考文献(24)
相关文章 (15)

全文: PDF (585 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨右美托咪定对脓毒症小鼠存活率的影响及脑保护作用并探讨其机制。方法 ICR雄性小鼠,体质量20～25 g，采用随机数字表法分为四组（n=20）：假手术（Sham）组、脓毒症（CLP）组、脓毒症+右美托咪啶（CLP+DEX）组及脓毒症+右美托咪啶+育亨宾（CLP+DEX+Y）组。CLP组通过盲肠结扎穿孔术（CLP）制备脓毒症小鼠模型，Sham组不进行盲肠结扎和穿孔，其余处理与模型组相同。CLP+DEX组于模型制备后0、2、4、6 h分别腹腔注射10 μg/kg右美托咪定，CLP+DEX+Y组除术后右美托咪定治疗还需于模型制备前30 min腹腔注射育亨宾3 mg/kg，其他组给予等量生理盐水。于术后24 h取小鼠脑组织，对其分别进行脑组织含水量、脑组织匀浆中丙二醛（MDA）含量及超氧化物歧化酶（SOD）活性、脑组织病理和脑细胞凋亡情况的检测。结果 CLP组小鼠脑组织含水量增加，脑组织匀浆中MDA含量明显增加，SOD活性明显降低，组织病理学细胞破坏增多、TUNEL染色阳性细胞数增多，10 μg/kg的右美托咪啶治疗可使这些变化明显缓解（P<0.05）。育亨宾能拮抗右美托咪定的保护效果。结论右美托咪定通过作用于α2肾上腺素受体对脓毒症小鼠脑损伤有明显的保护作用，其机制可能与其抗凋亡作用以及对内源性氧化还原平衡状态的维持有关。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王志勇
	杨永妍
	于泳浩

关键词 ：右美托咪定, 脓毒症, 脓毒症脑病, α2肾上腺素受体

通讯作者: 于泳浩（1970-），男，教授，主任医师，E-mail：yuyonghao@126.com。

作者简介: 王志勇（1965-），男，副主任医师，E-mail:wangzhiyongqw1@126.com。

引用本文:

王志勇，杨永妍，于泳浩. 右美托咪定对脓毒症小鼠的脑保护作用[J]. 中国急救医学, 2018, 38(12): 1090-1094.
Wang Zhi-yong, Yang Yong-yan, Yu Yong-hao. The protective effects of dexmedetomidine on sepsis-associated encephalopathy in mice. Chinese Journal of Critical Care Medicine, 2018, 38(12): 1090-1094.

链接本文:

http://www.cnemergency.org.cn/CN/10.3969/j.issn.1002-1949.2018.12.016 或 http://www.cnemergency.org.cn/CN/Y2018/V38/I12/1090

［1］Hotchkiss RS, Moldawer LL, Opal SM, et al. Sepsis and septic shock ［J］. Nat Rev Dis Primers, 2016, 2（6）: 16045. ［2］Jacob A, Brorson JR, Alexander JJ. Septic encephalopathy: inflammation in man and mouse［J］. Neurochem Int, 2011, 58(4):472-476. ［3］Iwashyna TJ, Ely EW, Smith DM, et al. Long-term cognitive impairment and functional disability among survivors of severe sepsis ［J］. JAMA, 2010, 304(16):1787-1794. ［4］Naaz S, Ozair E. Dexmedetomidine in current anaesthesia practice-a review ［J］. J Clin Diagn Res, 2014, 8(10):GE01-4. ［5］Erbatur ME, Sezen SC, Bayraktar AC, et al. Effects of dexmedetomidine on renal tissue after lower limb ischemia reperfusion injury in streptozotocin induced diabetic rats ［J］. Libyan J Med, 2017, 12(1):127. ［6］Riveros R, Makarova N, Riveros-Perez E, et al. Utility and clinical profile of dexmedetomidine in pediatric cardiac catheterization procedures: amatched controlled analysis［J］. Semin Cardiothorac Vasc Anesth, 2017, 21(4): 330-340. ［7］Luo C, Ouyang MW, Fang YY, et al. Dexmedetomidine Protects Mouse Brain from Ischemia-Reperfusion Injury via Inhibiting Neuronal Autophagy through Up-Regulating HIF-1α［J］. Front Cell Neurosci, 2017, 11: 197. ［8］Koca U, Olguner CG, Ergur BU, et al. The effects of dexmedetomidine on secondary acute lung and kidney injuries in the rat model of intra-abdominal sepsis［J］. ScientificWorldJournal, 2013, 2013:292. ［9］Xie K, Yu Y, Huang Y, et al. Molecular hydrogen ameliorates lipopolysaccharide-induced acute lung injury in mice through reducing inflammation and apoptosis ［J］. Shock, 2012, 37(5):548-555. ［10］Liu Z, Wang Y, Wang Y, et al. Dexmedetomidine attenuates inflammatory reaction in the lung tissues of septic mice by activating cholinergic anti-inflammatory pathway［J］. Int Immunopharmacol, 2016, 35（7）:210-216.  ［11］Liu Z, Wang Y, Ning Q, et al. The role of spleen in the treatment of experimental lipopolysaccharide-induced sepsis with dexmedetomidine［J］. Springerplus, 2015, 4（12）:800. ［12］Dejager L, Pinheiro I, Dejonckheere E, et al. Cecal ligation and puncture: the gold standard model for polymicrobial sepsis［J］. Trends Microbiol, 2011, 19(4):198-208. ［13］Vaughns JD, Martin C, Nelson J, et al. Dexmedetomidine as an adjuvant for perioperative pain management in adolescents undergoing bariatric surgery: an observational cohort study［J］. J Pediatr Surg, 2017, 52(11):1787-1790. ［14］Zhang Y, Jia S, Gao T, et al. Dexmedetomidine mitigate acute lung injury by inhibiting IL-17-induced inflammatory reaction［J］. Immunobiology, 2018, 223(1): 32-37. ［15］Chen Z, Ding T, Ma CG. Dexmedetomidine (DEX) protects against hepatic ischemia/reperfusion (I/R) injury by suppressing inflammation and oxidative stress in NLRC5 deficient mice［J］. Biochem Biophys Res Commun, 2017, 493(2): 1143-1150. ［16］Shen M, Wang S, Wen X, et al. Dexmedetomidine exerts neuroprotective effect via the activation of the PI3K/Akt/mTOR signaling pathway in rats with traumatic brain injury［J］. Biomed Pharmacother, 2017, 95（11）:885-893. ［17］Hoffman WE, Kochs E, Werner C, et al. Dexmedetomidine improves neurologic outcome from incomplete ischemia in the rat reversal by the alpha 2-adrenergic antagonist atipamezole ［J］. Anesthesiology, 1991, 75(2):328-332. ［18］Eser O, Fidan H, SahinO, et al. The influence of dexmedetomidine on ischemic rat hippocampus［J］. Brain Res, 2008, 1218:250-256.  ［19］Pandharipande PP, Sanders RD, Girard TD, et al. Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial［J］. Crit Care, 2010， 14(2):R38.  ［20］Guo F, Wang Q, Yan CY, et al. Clinical application of different sedation regimen in patients with septic shock［J］. Zhonghua Yi Xue Za Zhi, 2016, 96(22):1758-1761. ［21］Matsuda A, Jacob A, Wu R, et al. Novel therapeutic targets for sepsis: regulation of exaggerated inflammatory responses［J］. J Nippon Med Sch, 2012, 79(1): 4-18. ［22］Rodríguez-Rodríguez A, Egea-Guerrero JJ, Murillo-Cabezas F, et al. Oxidative stress in traumatic brain injury［J］. Curr Med Chem, 2014, 21(10):1201-1211. ［23］Bahar I, Elay G, Baskol G, et al. Increased DNA damage and increased apoptosis and necrosis in patients with severe sepsis and septic shock［J］. J Crit Care, 2017, 43:271-275. ［24］Oami T, Watanabe E, Hatano M, et al. Blocking liver autophagy accelerates apoptosis and mitochondrial injury in hepatocytes and reduces time to mortality in a murine sepsis model［J］. Shock, 2017, 10：1097.